Methods: We initially pilot tested the survey to 10 Massachusetts College of Pharmacy and Health Sciences (MCPHS)-Boston pharmacy practice faculty representing different practice areas. The questionnaire was modified based on faculty feedback. The final survey was prepared using eListen software and e-mailed in early January 2007 to 356 preceptors with an accompanying BV-6 nmr letter explaining the project. Preceptors were requested to reply by the end of January. Responses and free-text comments were recorded and descriptive statistics compiled.
Results: 152 preceptors responded (43% response rate). An equal number reported currently using
a PDA in practice compared with those not using one. Of those not using a PDA, 71% reported having other DI databases at their site. Preceptors believed that the PDA was most useful for general DI, scheduling and planning, and performing calculations. Free-text comments suggested that students need to be
able to evaluate DI software and not rely on it as the sole DI resource. The majority (96%) of preceptors believed that students should be trained on DI software.
Conclusion: Hand-held electronic devices were used by preceptors for a variety of reasons, and the majority of preceptors believed that training students on the use and evaluation of DI software was important.”
“Purpose of review
This check details review considers the use of eculizumab in the treatment of atypical haemolytic uraemic syndrome (aHUS) as well as the other complement-mediated renal diseases, including dense deposit disease (DDD) and C3 glomerulonephritis (C3GN). In addition, a brief discussion of the effectiveness of eculizumab for the prevention of antibody-mediated rejection (AMR) in the setting of renal transplant and the treatment of shiga toxin associated haemolytic uraemic syndrome
(STEC HUS) is also provided.
Recent findings
No randomized controlled trials exist to support the use of eculizumab in renal disease. The results of two unpublished, prospective adult and adolescent trials support its utility in aHUS, whereas retrospective data support the effectiveness in paediatric aHUS. These two data sets form the basis of the sole renal indication for eculizumab. One https://www.selleckchem.com/products/ly333531.html small, single-centre trial and a growing number of case reports support the use of eculizumab in C3 glomerulopathy (C3G). There are limited trial data in AMR and renal transplant. Finally, there are conflicting data for the use of eculizumab in STEC HUS.
Summary
The cumulative published data establish the effectiveness of eculizumab in a select group of renal diseases that have at the centre of their disease either abnormal complement control or maladaptive complement activation.”
“Objective. To determine whether first-trimester crown-rump length (CRL) is associated with birthweight extremes at term.
Methods.